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Abstract
Background: Differences in the determinants of Chlamydia trachomatis (’chlamydia’) and Mycoplasma genitalium
(MG) genital infection in women are not well understood.
Methods: A cohort study of 16 to 25 year old Australian women recruited from primary health care clinics, aimed
to determine chlamydia and MG prevalence and incidence. Vaginal swabs collected at recruitment were used to
measure chlamydia and MG prevalence, organism-load and chlamydia-serovar a cross-sectional analysis undertaken
on the baseline results is presented here.
Results: Of 1116 participants, chlamydia prevalence was 4.9% (95% CI: 2.9, 7.0) (n = 55) and MG prevalence was
2.4% (95% CI: 1.5, 3.3) (n = 27). Differences in the determinants were found - chlamydia not MG, was associated
with younger age [AOR:0.9 (95% CI: 0.8, 1.0)] and recent antibiotic use [AOR:0.4 (95% CI: 0.2, 1.0)], and MG not
chlamydia was associated with symptoms [AOR:2.1 (95% CI: 1.1, 4.0)]. Having two or more partners in last
12 months was more strongly associated with chlamydia [AOR:6.4 (95% CI: 3.6, 11.3)] than MG [AOR:2.2 (95% CI: 1.0,
4.6)] but unprotected sex with three or more partners was less strongly associated with chlamydia [AOR:3.1 (95%CI:
1.0, 9.5)] than MG [AOR:16.6 (95%CI: 2.0, 138.0)]. Median organism load for MG was 100 times lower (5.7 × 10
4/
swab) than chlamydia (5.6 × 10
6/swab) (p < 0.01) and not associated with age or symptoms for chlamydia or MG.
Conclusions: These results demonstrate significant chlamydia and MG prevalence in Australian women, and
suggest that the differences in strengths of association between numbers of sexual partners and unprotected sex
and chlamydia and MG might be due to differences in the transmission dynamics between these infections.
Background
Genital Chlamydia trachomatis (’chlamydia’) infection is
a significant public health problem among young Aus-
tralian women, with notification rates increasing from
74 per 100 000 people per year in 1997, to 287 per
100 000 people per year in 2009 [1]. Prevalence esti-
mates among young Australian women range from 3%
to 5% in community-based samples [2,3], but these esti-
mates are based on small sample sizes with limited
precision. In light of Australia’s future national chlamy-
dia testing pilot program [4], there is an urgent need for
reliable chlamydia prevalence estimates that can be used
to both inform the design of the pilot and monitor its
performance.
Mycoplasma genitalium (MG) is another important
sexually transmitted pathogen that is associated with ure-
thritis [5], cervicitis, endometritis [6], pelvic inflammatory
disease (PID), tubal factor infertility [7], and an increased
risk of HIV transmission [8]. Recent studies report varying
prevalence estimates for MG in women; 0.8% (95% confi-
dence interval [CI]:0.4, 1.6) among 18-27 year old
sexually-active women in the US [9]; 2.3% (95% CI:1.3,
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(95% CI:2.7, 4.3) in sexually-active students in the UK
[11]. However, differences in the type of specimens (urine
or swabs) and if applicable, how the specimens were
stored may contribute to these differences in prevalence
[12]. Overall, MG prevalence has been found to be consis-
tently lower than chlamydia [9-11]. In Australia, MG test-
ing is not widely available and there are no population
data. Understanding the burden of disease that might be
attributable to MG in young Australian women is neces-
sary to inform clinical practice and policy.
Our paper compares the epidemiological characteris-
tics of chlamydia and MG in a community-based sample
of sexually-active young women in order to gain insights
into the epidemiology and transmission dynamics of
these two infections within the same population. We
examine prevalence estimates and explore clinical and
behavioral factors associated with each infection. We
also present chlamydia and MG organism loads and
identified chlamydia serotypes.
Methods
Recruitment
The data presented in this paper were collected as part
of a longitudinal study of young women - the Chlamydia
Incidence and Re-infection Rates Study (CIRIS). The
primary aim of CIRIS was to measure chlamydia inci-
dence over 12 months; a secondary aim was to measure
MG incidence. Women were recruited from 29 primary
health clinics (including general practice, sexual health
and family planning clinics) in three states in Australia
between May 2007 and August 2008. Women were eli-
gible for inclusion if they were aged 16 to 25 years, had
ever had vaginal sex, were not pregnant at recruitment,
and were able to be contacted by post within Australia
during the 12 month study. A dedicated research assis-
tant recruited consecutive women attending the clinic
during a six week period. Informed consent was
obtained for each participant prior to their recruitment
into the study. Further methodological details are pub-
lished elsewhere [13]. The prevalence estimates and
other data presented here are based on testing and data
collection at the time of recruitment (baseline).
Testing
At baseline, each participant provided two self-collected
vaginal swabs. One swab was tested for chlamydia by
the clinic’s preferred pathology testing laboratory using
nucleic acid amplification techniques (NAAT). The sec-
ond swab, a flocked swab http://www.microrheologics.
com, was forwarded to Royal Women’s Hospital (RWH),
Melbourne, Victoria for MG testing and further studies
including organism load quantification and chlamydia
serovar determination if diagnosed chlamydia positive.
MG testing was conducted by rotating the swab in 400
μl of PBS and 200 μl was extracted using the automated
MagNA Pure LC (Roche Molecular Biochemical, Man-
nheim, Germany) with the DNA Isolation Kit 1 protocol.
Detection of MG was performed using the extracted DNA
amplified by real-time PCR targeting a 517 bp region of
the 16 S rRNA gene [14] and human beta-globin was used
as a measure of sample adequacy as an internal control to
detect the presence of possible inhibitors [15]. Any
remaining specimen was stored at -80°C. All the partici-
pants were tested for MG at baseline, six months and 12
months throughout the study period. The MG test results
were validated by retesting all MG positive samples and
retesting a random sample of 836 stored study samples
from all the swabs collected during the study period, at
the conclusion of the study using a real-time PCR assay
that was directed at the adhesion protein gene (MgPa)
[16,17]. This sample size was selected in order to obtain a
precision of 4% around a sensitivity of 97%. We found a
kappa value of 0.97 (95% CI: 0.94 to 1.01), (sensitivity
95.0% and specificity 99.6%) between the two assays [18].
Women were given a positive MG diagnosis if they tested
positive using either assay; this accounted for any possible
DNA degradation of the sample during the storage period,
and also, in the absence of a clear gold standard for the
diagnosis of MG, it was clinically important to treat all
women who were MG positive by either assay.
Organism load and serovars
Quantification of chlamydia load was determined by a
quantitative PCR (qPCR) system targeting the omp1
gene using published methodology [19]. The chlamydial
load in each tested sample was quantified by comparing
the crossing-threshold of each sample to the crossing-
threshold of a standard curve constructed by amplifying
different known copy numbers of the omp1 gene. This
method also determined whether any mixed infections
were present, and identified the chlamydia serovar(s) of
each infection through a series of qPCR assays using
serovar-specific probes. Confirmation of each chlamydia
serovar, and detection of genotypic variants were deter-
mined by DNA sequencing across all four variable
domains of the omp1 gene that encodes for the anti-
genic major outer membrane protein as previously
described [20].
The MG concentration of each sample was quantified
using a qPCR (TaqMan
® MGB Probe) assay targeting
the MgPa gene [21]. Quantification was carried out
using a LightCycler 480 Real-Time PCR System (Roche
Diagnostics, Mannheim, Germany) by comparing the
quantification cycle of each sample to the quantification
cycle of a standard curve constructed by amplifying dif-
ferent known copy numbers of target gene. Organism
loads were presented as copies per swab.
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Women who tested positive for chlamydia at baseline
w e r em a n a g e db yt h ec l i n i cf r o mw h e r et h e yw e r e
recruited. The treating clinicians were provided with
up-to-date chlamydia treatment guidelines (1 g of azi-
thromycin for uncomplicated chlamydia infection) and
partner notification material [22]. Subsequent follow-up
surveys determined if treatment had been taken and if
partner(s) had been treated. All women who tested posi-
tive were asked to re-test for chlamydia three months
after treatment.
All women who tested positive for MG were managed
by the research team and a sexual health physician. Clini-
cal symptoms and partner notification were discussed
and support material and partner notification letters
were provided. Treatment with 1 g of azithromycin [23]
was provided if there were no symptoms to suggest PID.
Women were sent a second vaginal swab for a test-of-
cure one month following treatment. If the test-of-cure
was positive and no risk of re-infection was identified via
telephone consultation, the patient was treated with 400
mg moxifloxacin daily for 10 days [24], otherwise a repeat
1 g dose of azithromycin was prescribed [24] and another
test-of-cure was done a month later.
Data collection
Women were asked to complete a self-administered
questionnaire at recruitment. This collected demo-
graphic, sexual behaviour data (including number of sex
partners), and recent antibiotic and contraceptive use. It
also included questions about the presence of any geni-
tal symptoms during the month prior to recruitment,
including abnormal vaginal discharge and pelvic pain.
Statistical methods
Power calculations assuming a design effect of 2 sug-
gested that a sample size of 1,000 would be sufficient to
generate standard error of 0.8% and 0.6% for prevalence
estimates of 5% and 2% respectively.
Data were analysed using STATA version 10.2 [25].
All analyses were adjusted for clustering at the clinic
level and for type of clinic (general practice versus sex-
ual health/family planning clinic). Prevalence estimates
and 95%confidence intervals (95% CIs) were calculated
and odds ratios (OR) and robust standard errors were
calculated to explore associations with chlamydia and
MG. For the analysis of the associations with chlamydia
or MG and symptoms, only women who had tested
positive for one infection were included and women
with a co-infection were excluded. Associations with
organism load for both chlamydia and MG were
explored using linear regression and organism load was
logarithm transformed because of the skewed distribu-
tion of the raw data.
Ethics approval to conduct this study was obtained
from ten Human Research Ethics Committees through-
out Australia.
Results
Characteristics of sample
Overall, 66% of consecutive, eligible women agreed to
participate in the study (n = 1116) with two-thirds
recruited from general practice clinics (20 out of 29
clinics). The participants had a median age of 21 years,
and when compared with the most recent Australian
census data for women in the same age group, the study
participants were more likely to be Australian-born
(89% versus 79%, p < 0.01) [26] and more well-educated
(tertiary degree 44% versus 21% p < 0.01) [26]. Com-
pared with women of the same age in the ‘Australian
Study of Health and Relationships’ (a nationally repre-
sentative sexual behaviour survey), women in our study
were more likely to report having had three or more
sexual partners in the last 12 months (33% versus 9.5%,
p < 0.01) [27]. There were no differences for all other
reported demographics according to the Australian
Bureau of Statistics census data [26].
Prevalence estimates and associations
A total of 55 women tested positive for chlamydia [preva-
lence: 4.9% (95% CI:2.9, 7.0)] and 27 tested positive for
MG [prevalence: 2.4% (95% CI:1.5, 3.3)]. Two women
were co-infected with both chlamydia and MG [0.2%
(95% CI:0.0, 0.4)]. Prevalence estimates were higher
among women recruited from sexual health clinics than
from general practice clinics for both chlamydia [7.9%
(95% CI:4.1, 11.8) compared with 3.4% (95% CI:1.5, 5.3)
(p = 0.01)], and MG [4.0% (95% CI:2.7, 5.3) versus 1.6%
(95% CI:0.7-2.6) (p < 0.01)] respectively (Table 1).
Chlamydia was associated with younger age [AOR:0.9
(95% CI: 0.8, 1.0)] whereas MG was not. MG was asso-
ciated with Indigenous status [AOR:4.5 (95% CI:1.4,
14.9)] (n = 2); a strong association was found between
chlamydia infection and increased numbers of sexual
partners. The odds of testing positive for chlamydia were
six times greater for women who had had two or more
sexual partners in the preceding year compared with
women with fewer partners [AOR:6.4 (95% CI:3.6, 11.3)],
the association was not as strong for MG [AOR:2.2 (95%
CI:1.0, 4.6)]. In contrast, the odds of infection associated
with the reported number of unprotected sex partners
was far greater for MG [≥3 unprotected sex partners in
the last 12 months: AOR:16.6 (95% CI:2.0, 138.0)] than
for chlamydia [≥3 unprotected sex partners in the last 12
months: AOR:3.1 (95% CI:1.0, 9.5)]. Having being diag-
nosed with chlamydia in the past was also associated
with testing positive for chlamydia [AOR:2.0 (95% CI:1.1,
3.9)], but not for MG (Table 1).
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months was inversely associated with chlamydia
[AOR:0.4 (95% CI:0.2, 1.0)], but was not associated with
MG [AOR:0.8 (95% CI:0.3, 2.5)]. There were no associa-
tions with any other demographic characteristics
collected (country of birth, employment status or educa-
tion level) and chlamydia or MG (Table 1).
Chlamydia was not associated with any self-reported
g e n i t a ls y m p t o m sb u tM Gw a sa s s o c i a t e dw i t hs e l f -
reported ‘abnormal vaginal discharge’ [AOR:2.1 (95%
Table 1 Characteristics for women who tested positive for Chlamydia trachomatis or Mycoplasma genitalium
Variable Participants’
characteristics
N (%)
Chlamydia
Prevalence (95%CI
b)
(no.
c positive/no.
total women)
UOR
d
(95% CI)
AOR
e (95%
CI)
MG Prevalence (95%
CI)
(no. positive/no.
total cases)
UOR (95%
CI)
AOR (95%
CI)
Age
a (median age) 0.9 (0.8,
1.0)
0.9 ( 0.8, 1.0) 1.0 (0.8, 1.3) 1.0 (0.8, 1.3)
Country of birth
Not Australian born 121 (11.5) 1.7 (0.4, 6.7) (2/121) 1.0 1.0 1.7 (0.5, 5.2) (2/120) 1.0 1.0
Australian born 934 (88.5) 5.4 (3.5, 8.1) (50/934) 3.4 (0.7,
16.6)
3.1 (0.6, 14.7) 2.6 (1.5, 3.7) (24/929) 1.6 (0.4, 6.2) 1.4 (0.3, 5.9)
Indigenous status
Not indigenous 1059 (97.7) 4.8 (3.2, 7.3) (51/1059) 1.0 1.0 2.4 (1.4, 3.4) (25/1059) 1.0 1.0
Indigenous 25 (2.3) 4.0 (0.5, 27.2) (1/25) 0.8 (0.1,
6.0)
1.0 (0.1,8.0) 8.0 (2.4, 23.2) (2/25) 3.6 (0.9, 13.5) 4.5 (1.4, 14.9)
Education
up to year 12
f 609 (56.1) 5.9 (2.9, 8.9) (36/609) 1.0 1.0 3.1 (1.8, 4.4) (19/604) 1.0 1.0
Tertiary 477 (43.9) 3.6 (1.4, 5.7) (17/477) 0.6 (0.3,
1.2)
0.6 (0.3, 1.3) 1.7 (0.4, 2.9) (8/476) 0.5 (0.2, 1.1) 0.6 (0.3, 1.2)
Employment
Unemployed/Not
working
418 (38.5) 4.8 (1.8, 7.8) (20/418) 1.0 1.0 2.4 (0.7, 4.1) (10/416) 1.0 1.0
Employed 668 (61.5) 4.9 (2.7, 7.1) (33/668) 1.0 (0.6,
1.9)
1.0 (0.5, 1.9) 2.5 (1.6, 3.5) (17/664) 1.1 (0.5, 2.1) 1.0 (0.5, 2.1)
Clinic type
GP 738 (66.1) 3.4 (1.5, 5.3) (25/738) 1.0 N/A
g 1.6 (0.7, 2.6) (12/735) 1.0 N/A
g
SHC/FP 378 (33.9) 7.9 (4.1, 11.8) (30/378) 2.5 (1.2,
4.9)
4.0 (2.7, 5.3) (15/375) 2.5 (1.4, 4.6)
No. partners last 12
months
<2 553 (51.8) 1.3 (0.5, 2.1) (7/553) 1.0 1.0 1.4 (0.6, 2.3) (8/551) 1.0 1.0
2+ 515 (48.2) 8.5 (5.6, 11.5) (44/515) 7.3 (4.3,
12.2)
6.4 (3.6, 11.3) 3.7 (2.1, 5.3) (19/511) 2.6 (1.3, 5.3) 2.2 (1.0, 4.6)
Partners 12 months
without condoms
0 301 (29.0) 3.0 (1.5, 6.1) (9/301) 1.0 1.0 0.3 (0.0, 2.3) (1/299) 1.0 1.0
1-2 599 (57-8) 4.3 (2.6, 6.6) (26/599) 1.5 (0.8,
2.9)
1.4 (0.7, 2.6) 2.5 (1.6, 3.9) (15/595) 7.7 (1.0, 62.4) 7.2 (0.9, 57.6)
3+ 137 (13.2) 10.9 (6.4, 18.0) (20/216) 4.0 (1.6,
10.1)
3.1 (1.0, 9.5) 6.6 (3.7, 11.5) (9/137) 20.9 (2.6,
167.3)
16.6 (2.0,
138.0)
Past history of
Chlamydia diagnosis
1.0 1.0
No 965 (89.4) 4.2 (2.2, 6.3) (41/965) 1.0 1.0 2.4 (1.4, 3.4) (23/960) 1.5 (0.6, 4.0) 1.3 (0.4, 3.6)
Yes 114 (10.6) 9.6 (5.1, 14.2) (11/114) 2.4 (1.2,
4.7)
2.0 (1.1, 3.9) 3.5 (0.3, 6.8) (4/113)
Antibiotics in last 2
months
No 807 (74.0) 5.7 (3.0, 8.4) (48/833) 1.0 1.0 2.5 (1.6, 3.9) (21/802) 1.0 1.0
Yes 283 (26.0) 2.5 (0.5, 4.4) (7/283) 0.4 (0.2,
1.0)
0.4 (0.2, 1.0) 2.1 (0.8, 5.5) (6/282) 0.8 (0.3, 2.6) 0.8 (0.3, 2.5)
a Represents change in odds of infection with each additional year of age.
b CI: confidence interval.
c no.= number.
d Unadjusted odds ratio.
e Adjusted Odd
Ratio: Adjusted for clinic type the participants were recruited from.
f Year 12 is the final year of secondary education in Australia.
g Data not available.
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reported a greater number of symptoms on average than
women testing positive for chlamydia, although this did
not reach statistical significance (1.9 symptoms versus
1.3; p = 0.2).
Infectious load and serovars
Overall, 52 chlamydia-positive samples and 22 MG posi-
tive samples were analysed to determine their respective
infectious loads. The median MG organism load was 100
times lower (5.7 × 10
4/swab) than the median chlamydia
organism load (5.6 × 10
6/swab) (p < 0.01), and the quan-
titative range reported for MG was smaller (1.9 × 10
3/
swab to 2.1 × 10
6/swab) than for chlamydia (4.2 × 10
3/
swab to 2.6 × 10
9/swab) (Figure 1) There were no asso-
ciations between self-reported symptoms, a past history
of chlamydia or age and organism load for either chlamy-
dia or MG (data not shown).
The chlamydia serovar was identified for 52 of 55 posi-
tive chlamydia specimens and 27 (51.9%) of these were
serovar E and shared a 100% homology in their omp1
gene sequencing (Table 3). No cases of mixed chlamydia
serovar were detected. The organism load was signifi-
cantly higher for serovar D than serovar E (p = 0.04) and
higher for serovar E than for serovar F (p =0 . 0 6 ) .N o
other differences were found (Figure 2) and no associa-
tions between chlamydia serovar and age were found
(data not shown).
MG test-of-cure
Of the 27 women who were sent a second swab in the
mail for an MG test-of-cure one month after azithromy-
cin treatment, 20 (74%) returned swabs for testing. Of
these, 17 tested negative, and three (15%) tested positive.
The three women with persistent MG had further tele-
phone consultations with a sexual health clinician who
determined all had adhered to treatment, two had had
partners concurrently treated with 1 g azithromycin,
and one had no sexual contact since her diagnosis.
These women were considered likely to have had treat-
ment failure rather than a new infection [azithromycin
failure: 15% (95% CI:3.2, 37.9)] and were prescribed 400
mg moxifloxacin daily for ten days. A second test-of-
cure was performed one month later on two of the
three women and both were negative, but the third
woman failed to return a second test-of-cure.
Discussion
This paper presents the largest community-based estimate
of chlamydia prevalence among young Australian women
and Australia’s first MG prevalence survey. Consistent
with previous international reports, we found the chlamy-
dia prevalence (4.9%) was higher than the MG prevalence
(2.4%) among young women [9-11]. We also found some
important clinical and epidemiological differences between
chlamydia and MG in this cohort, suggesting different
transmission dynamics between the two infections.
Firstly, it is possible that MG is less infectious than
chlamydia requiring a greater “exposure” or direct geni-
tal or cervical contact to acquire MG. This is supported
by the 100 fold lower organism load among samples
from women with MG compared with chlamydia, and
the finding that MG was more strongly associated with
unprotected sex than chlamydia. Clearly, further partner
studies are needed to investigate the transmission
dynamics for MG and chlamydia to determine if and
how transmission dynamics differ.
The clinical features associated with MG and chlamy-
dia also differed, MG was associated with vaginal dis-
charge, but chlamydia showed no associations with any
reported symptoms. Studies of the association between
MG and specific genital symptoms have been somewhat
conflicting with some studies determining an association
between MG and genito-urinary symptoms including
vaginal discharge and dysuria [28], and other studies
finding no association with symptoms [29]. Overall,
published data suggests that MG appears to be some-
what similar to chlamydia [10,29-31]. Further to this, no
associations were found between organism load and
reported symptoms for either chlamydia or MG, which
was also consistent with the other studies [30].
Younger women were more likely to have a prevalent
chlamydia infection which is consistent with other
research [2], although younger age was not associated
with MG infection.
Antibiotic use in the two months prior to being tested
demonstrated a protective effect against chlamydia but
not for MG. This is most likely because chlamydia has
been shown to be sensitive to a number of commonly
prescribed antibiotics [32], and MG is less likely to be
sensitive to the same prescribed antibiotics [23,32-34].
We also found that MG but not chlamydia was asso-
ciated with Indigenous status (Australian Aboriginal and
Torres Strait Islander women). The number of Indigen-
ous women in our study (n = 25) limited further
exploration in the analysis. Nonetheless, these are the
first prevalence estimates for MG in Indigenous Austra-
l i a nw o m e na n dg i v e nt h a tS TI rates are generally
higher in Indigenous women in Australia this is not a
surprising MG finding [35].
Unlike other studies, we did not find any associations
between chlamydia organism load and age or past his-
tory of chlamydia infection [30,36]. We did find evi-
dence to suggest that chlamydia serovar was associated
with organism load. However, this was based on a small
number of cases. Nevertheless, given that others have
not found any association between serovar and organism
load [30], and uncertainty remains as to whether serovar
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larger sample sizes are needed to investigate serovar and
organism load.
There were a number of limitations to our study. Firstly,
our sample had a higher proportion of Australian-born,
well-educated and sexually-active women than the general
b a c k g r o u n dp o p u l a t i o ni nA u s t r a l i af o rt h es a m ea g e
[26,27], however, these are common findings in similar
research studies investigating sexual health issues [2,37]. It
is difficult to assess the impact this may have had on our
prevalence estimates because increased number of part-
ners is often associated with increased prevalence [2,38]
and higher education levels tend to be associated with
reduced prevalence. We also were unsuccessful in recruit-
ing 34% of the eligible women who were approached in
the clinics, and while there were no associations between
age and participation, we have no other information about
the women we were unable to recruit. Nevertheless, this
participation compares favorably with other chlamydia
prevalence surveys [39-41].
Another limitation was relying on self-reported genital
symptoms; these have been found to be highly subjective,
non-specific and frequently poorly associated with cervical
STIs. Self-reporting of genital symptoms on questionnaires
also do not always correlate well with clinician elicited
symptoms [42]. We audited the clinical notes of a sub-set
of 100 women and found very poor correlation with genital
symptoms reported in the clinical notes (data not shown).
Women were far more likely to self-report symptoms on
their study questionnaire than were recorded by their clini-
cians in their clinical notes at the time of recruitment.
There were limitations to the organism load analysis.
Samples were self-collected and therefore the equal effi-
ciency of sampling could not be assured, and as positive
samples were subjected to a number of assays, the mean
organism loads were not able to be normalized to num-
ber of cells per sample. However, we did find that the
serovars detected in our study were consistent with
those reported in international data (serovar E followed
by serovar F) [30,43].
There were a number of strengths to this study
including the large sample size, the high participation
rate of 66% and the broad range of geographical loca-
tions and socio-economic areas from where the women
Table 2 Associations between self-reported symptoms and infection with Chlamydia trachomatis or Mycoplasma
genitalium (MG)
Symptoms in last month Chlamydia % (95% CI
a)
(n/no. women)
UOR
b
(95% CI)
AOR
c
(95% CI)
MG % (95% CI)
(n/no. women)
UOR
(95% CI)
AOR
(95% CI)
Abnormal discharge
No 4.6 (2.9, 7.2) (40/840) 1.0 1.0 1.8 (1.1, 2.8) (15/836) 1.0 1.0
Yes 4.8 (2.9, 7.8) (12/249) 1.0 (0.6, 1.7) 0.9 (0.6, 1.5) 4.0 (1.8, 6.2) (10/248) 2.3 (1.2, 4.6) 2.1 (1.1, 4.0)
Abnormal vaginal odour
No 4.3 (2.8, 6.5) (40/902) 1.0 1.0 2.0 (1.3, 3.2) (18/898) 1.0 1.0
Yes 6.4 (3.0, 13.4) (12/187) 1.5 (0.7, 3.3) 1.4 (0.6, 3.1) 3.8 (1.7, 8.0) (7/186) 1.8 (0.7, 4.5) 1.7 (0.7, 4.2)
Burning when passing urine
No 4.3 (2.7, 6.6) (39/888) 1.0 1.0 2.3 (1.6, 3.3) (20/883) 1.0 1.0
Yes 6.5 (3.6, 11.4) (13/201) 1.5 (0.9, 2.8) 1.5 (0.8, 2.6) 2.5 (1.2, 5.3) (5/201) 1.0 (0.5, 2.2) 1.0 (0.5, 2.1)
Abdominal pain
No 4.6 (3.0, 6.9) (36/770) 1.0 1.0 2.0 (1.2, 3.1) (15/762) 1.0 1.0
Yes 5.0 (2.8, 8.8) (16/319) 1.1 (0.7, 1.8) 1.1 (0.6, 1.8) 3.1 (1.8, 5.4) (10/318) 1.6 (0.8, 3.4) 1.6 (0.7, 3.3)
Dyspareunia
No 5.1 (3.2, 7.9) (45/849) 1.0 1.0 2.1 (1.4, 3.1) (18/860) 1.0 1.0
Yes 3.2 (1.5, 6.8) (7/220) 0.6 (0.3, 1.4) 0.6 (0.2, 1.4) 3.2 (1.6, 6.3) (7/220) 1.5 (0.7, 3.3) 1.5 (0.7, 3.1)
Intramenstrual bleeding
No 4.8 (3.2, 7.3) (43/874) 1.0 1.0 2.0 (1.3, 3.0) (17/865) 1.0 1.0
Yes 4.2 (2.3, 7.5) (9/215) 0.9 (0.5, 1.4) 0.8 (0.5, 1.3) 3.7 (1.8, 7.4) (8/215) 1.9 (0.8, 4.6) 1.8 (0.7, 4.4)
Number of symptoms:
0 4.1 (2.6, 6.4) (19/461) 1.0 1.0 1.3 (0.6, 2.6) (6/456) 1.0 1.0
1 5.0 (2.7, 9.0) (11/222) 1.2 (0.7, 2.2) 1.1 (0.6, 2.1) 2.7 (1.4, 5.2) (6/222) 2.1 (0.8, 5.6) 2.0 (0.8, 5.2)
2 6.4 (3.2, 12.2) (13/204) 1.6 (0.8, 3.2) 1.5 (0.7, 3.0) 2.5 (0.1, 5.9) (5/204) 1.9 (0.5, 7.0) 1.8 (0.5, 6.4)
3 5.3 (2.4, 11.2) (5/95) 1.3 (0.5, 3.4) 1.2 (0.5, 3.1) 4.3xi (1.7, 9.9) (4/94) 3.3 (0.9, 12.1) 3.1 (0.8, 11.2)
4 4.6 (1.6, 12.8) (3/65) 1.1 (0.5, 2.8) 1.1 (0.4, 2.7) 1.5 (0.2, 10.8) (1/65) 1.2 (0.1, 10.9) 1.1 (0.1, 10.1)
5 3.3 (0.5, 20.8) (1/30) 0.8 (0.1, 6.4) 0.7 (0.1, 4.9) 10.0 (3.3, 26.5) (3/30) 8.3 (2.1, 32.5) 7.0 (1.9, 25.5)
6 0.0 (0/11) 0.0 (0/11)
a CI: confidence interval.
bUnadjusted odds ratio.
cAdjusted Odd Ratio: Adjusted for clinic type the participants were recruited from.
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Page 6 of 9were recruited. Also, considering 66% of the women
were recruited from general practice, and between 80 to
90% of young Australian women visit a general practice
clinic each year [4], the study method chosen was likely
to provide a broadly representative sample.
The prevalence of chlamydia in our study was higher
(4.9%) compared with the only other Australian popula-
tion-based chlamydia prevalence study for women in the
same age range (3.7%) [2] but was similar to a small
community-based study [3], and other studies involving
young women [44,45]. Importantly our data suggest
chlamydia prevalence is still somewhat lower in Austra-
lia than some other countries, most notably the UK [46].
These are the first population data on MG preva-
lence in Australia and our findings are very similar to
the population data to date from international studies
[2.3% (95%CI:1.3, 3.2)] [10], and [3.4% (95% CI:2.7,
4.3)] [11], but are somewhat higher than a study in the
U.S [0.8% (95% CI:0.4, 1.6)] [9]. As increasing evidence
supports a role for MG in PID and tubal factor inferti-
lity, MG is emerging as an important treatable STI in
women. Worryingly, consistent with other published
studies, we found that 1 g of azithromycin appears to
be 85% effective at best for uncomplicated MG [24,33].
Further, MG is less responsive to the doxycycline and
cefoxitin based regimens used in the presumptive
treatment with in women with PID [47]. Clearly our
data provide evidence that MG is not uncommon in
young women in Australia, and impetus is needed for
the commercialization of a diagnostic assay to improve
the management of MG. This study also contributes to
our understanding of the MG organism load in clinical
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Figure 1 Chlamydia trachomatis (chlamydia) organism load and
Mycoplasma genitalium (MG) organism load per swab (log).
Table 3 Serovars detected in Chlamydia trachomatis positive samples
Nucleotide Variant change Genbank accession number
Chlamydia genotype Frequency N (%) Position
a Nucleotide Amino acid Reference strain Reference This study
D 2 (3.6) - - - D-IC-CAL8 DQ06428 HM230054
E 27 (49.0) - - - E-Bour X52557 HM230055
E variant
b 1 (1.8) 372 C > T Silent (C) E-Bour X52557 HM230056
F 12 (21.8) - - - F-IC-Cal13 X52080 HM230057
G 3 (5.5) - - - G-DK-K1 AM90115 HM230058
G variant
c 2 (3.6) 487; 1003 A > G; T > G S > G; S > A G-DK-K1 AM90115 HM230059
Ia 1 (1.8) - - - Ia-IU-TC0167ut FJ26194 HM230061
J 1 (1.8) - - - J-UW-36 DQ06429 HM230062
K 3 (5.5) - - - K-UW-31 DQ06429 HM230063
N/A
d 2 (3.6)
Total 55
a - based on reference strain omp1 sequence.
b - E variant has 100% homology to Genbank sequence GU903922 (C. trachomatis strain 1969 from Australian MSM population).
c - G variant has 100% homology to Genbank sequence FJ261928 (G/IU-FW0267).
d - N/A: serovar unable to be determined.
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Figure 2 Chlamydia trachomatis (chlamydia) organism load per
swab (log) for each chlamydia serovar detected.
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Page 7 of 9samples. However, further studies are needed to be
done to understand this compared with other STIs
such as chlamydia and if there is any relationship
between copy number and pathogenicity.
Conclusions
This is the first large and broadly representative chlamydia
prevalence survey and first MG prevalence survey in Aus-
tralian women. Chlamydia prevalence was high in young
sexually-active women in Australia and largely asympto-
matic, supporting the need for further chlamydia control
activities. There is also a significant burden of MG in this
population, but importantly, this study identified that
there are important differences in the epidemiology of
chlamydia and MG and possibly in the transmission
dynamics of these two infections. This is important infor-
mation which contributes to the scant population data on
MG, an emerging pathogen in young women.
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